Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Nature Medicine, Published online: 07 June 2026; doi:10.1038/s41591-026-04479-3 As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).